STOCK TITAN

REGENXBIO Inc. - $RGNX STOCK NEWS

Welcome to our dedicated page for REGENXBIO news (Ticker: $RGNX), a resource for investors and traders seeking the latest updates and insights on REGENXBIO stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect REGENXBIO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of REGENXBIO's position in the market.

Rhea-AI Summary
REGENXBIO Inc. will participate in investor conferences on September 12 and 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
conferences
-
Rhea-AI Summary
RGX-181 trial shows well-tolerated gene therapy with reduced seizure frequency and improved skills
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
-
Rhea-AI Summary
REGENXBIO Inc. presents interim clinical trial data at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023, showcasing progress in gene therapies for neurodegenerative disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
Rhea-AI Summary
REGENXBIO announces progress on '5x'25' strategy, with updates on multiple gene therapy programs. Interim results from trials show positive safety and efficacy data. Enrollment completed for Phase III trial of RGX-121. $415 million in cash as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
conferences earnings
Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) will present data for ABBV-RGX-314, an investigational one-time AAV therapeutic, at the ASRS Annual Scientific Meeting. The presentations will include new interim data from the pharmacodynamic study of ABBV-RGX-314 delivered subretinally. Three presentations will cover Neovascular AMD and Diabetic Retinopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
-
Rhea-AI Summary
REGENXBIO Inc. announces interim results from Phase II AAVIATE and ALTITUDE trials, with zero cases of intraocular inflammation. Initial safety results from the AFFINITY DUCHENNE study support a well-tolerated profile. A new program in Duchenne with preclinical data using innovative science to produce near full-length wild-type dystrophin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.89%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
REGENXBIO Inc.

Nasdaq:RGNX

RGNX Rankings

RGNX Stock Data

592.06M
37.36M
7.18%
81.62%
8.05%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ROCKVILLE